Advertisement
Tuesday, November 17, 2026NewslettersAdvertiseWatch FL1
GET LOCALGo ad-freeHigh school sportsLocal eventsObituaries
Life

How Lipson Cancer Institute uses tumor testing to guide cancer treatment

Rochester Regional Health’s Lipson Cancer Institute uses tumor testing to help determine which treatments may be available to eligible patients. The institute also participates in a national program that matches patients with certain newly diagnosed blood disorders to clinical trials.

How Lipson Cancer Institute uses tumor testing to guide cancer treatment

Two patients with the same type of cancer may have different treatment options because their tumors carry different genetic changes. At Rochester Regional Health’s Lipson Cancer Institute, doctors use those differences to help choose treatments for eligible patients, including some with non-small cell lung cancer.

The approach, called precision oncology, adds information about a tumor’s DNA and proteins to what doctors already know about where it started and how it looks under a microscope. In Rochester Regional Health’s explainer, Lipson oncologist and hematologist Rachel David describes how those clues, known as biomarkers, can help doctors classify a cancer and see whether a treatment is available for a particular tumor feature.

DiSanto Propane (Billboard)

What a tumor sample can reveal

Doctors can test tissue from a biopsy in several ways. A lab technique called immunohistochemistry looks for specific proteins or other markers in the sample. Next-generation sequencing examines the tumor’s DNA for genetic changes that may help guide treatment and typically takes longer, according to the health system.

A test result can help the care team decide whether an available therapy is a match. David pointed to pembrolizumab, an immunotherapy that can be used for certain advanced cancers with a marker known as mismatch repair deficiency. For eligible patients, that marker can guide treatment across cancers that began in different organs.

Where testing has changed treatment options

David cited non-small cell lung cancer as an area where the approach has expanded treatment options. Some patients may qualify for drugs targeting changes involving EGFR, ALK or a specific alteration called KRAS G12C. David said targeted treatment can help some people with incurable lung cancer linked to an ALK rearrangement live for years while maintaining quality of life. She also cited advances in breast cancer and acute leukemia.

The bigger picture

Rochester Regional Health

More reporting on this topic.

Explore this topic →

At Lipson, the decision to pursue a targeted treatment also depends on the type of cancer, how long a patient can safely wait for test results and whether insurance will cover the therapy, Rochester Regional Health said.

How Lipson matches patients to clinical trials

Lipson participates in MyeloMATCH, a national clinical trial program for people newly diagnosed with acute myeloid leukemia or myelodysplastic syndromes. Maria Sbenghe is the local principal investigator, according to Rochester Regional Health.

Through the program, doctors use biomarkers from a patient’s sample to look for a trial that fits the molecular features of the disease. The studies evaluate treatments matched to those features.

Categories: LifeWellness

Want to go ad-free?

Become an FL1 member and say goodbye to ads! Plus, you’ll be supporting a company rooted in the Finger Lakes for nearly 30 years.

$4.99 / month

Get ad-free access

Renews monthly. Cancel anytime through your account. Already contributing via Google? Sign in with your Google account and unlock ad-free access. Embedded YouTube videos and other third-party media players may still contain ads.

Start your day with FingerLakes1

Get the stories that matter from across the Finger Lakes, delivered to your inbox.

Your email will be added to our newsletter mailing list, hosted on Substack. Privacy policy